ReviewBiology2026
Natural Killer Cell Immunotherapy in Solid Tumors: Microenvironmental Obstacles and Translational 3D Models.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Natural killer (NK) cells represent a promising tool for cancer immunotherapy; however, their efficacy against solid tumors is severely limited by the hostile tumor microenvironment (TME). This review provides a comprehensive overview of the physical, molecular, and metabolic barriers that drive NK cell dysfunction and immune evasion, emphasizing the physical challenge posed by extracellular matrix (ECM) density, which restricts infiltration. Beyond structural barriers, we examine the role of immunosuppressive cytokines (e.g., TGF-β) and immune checkpoint upregulation, both of which directly inhibit NK cell activation. Furthermore, NK cell signaling and cytotoxicity are profoundly affected by metabolic stressors such as hypoxia and acidosis, which act synergistically with the accumulation of immunosuppressive metabolites, including adenosine. These factors impair antitumor activity through multiple mechanisms, particularly the shedding of activating ligands. To investigate these complex interactions, we evaluate the advantages and disadvantages of different three-dimensional (3D) preclinical platforms, including tumor spheroids and Organ-on-Chip technologies, highlighting their distinct characteristics. Rather than advocating for a single technology, we emphasize that each model offers unique advantages for studying specific physical, chemical, and cellular components of the TME. Ultimately, leveraging the capabilities of these advanced 3D platforms is essential for deciphering microenvironmental barriers and unlocking the full therapeutic potential of NK cells against solid tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.